Zerbaxa | Dosage/Direction for Use

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Dosage/Direction for Use

Recommended Dosage: The recommended dosage of ZERBAXA in patients 18 years and older with creatinine clearance (CrCl) greater than 50 mL/min is 1.5 gram (g) (ceftolozane 1 g and tazobactam 0.5 g) for cIAI and cUTI and 3 g (ceftolozane 2 g and tazobactam 1 g) for HABP/VABP administered every 8 hours by intravenous infusion over 1 hour. The duration of therapy should be guided by the severity and site of infection and the patient's clinical and bacteriological progress as shown in Table 8. (See Table 8.)

Click on icon to see table/diagram/image

Dosage Adjustments in Patients with Renal Impairment: Dose adjustment is required for patients 18 years and older with CrCl 50 mL/min or less (Table 9). All doses of ZERBAXA are administered over 1 hour. For patients with changing renal function, monitor CrCl at least daily and adjust the dosage of ZERBAXA accordingly [see Patients with Renal Impairment under Precautions and Pharmacology: Pharmacokinetics under Actions]. (See Table 9.)

Click on icon to see table/diagram/image

Zerbaxa Dosage/Direction for Use

ceftolozane + tazobactam

Manufacturer:

MSD

Distributor:

Zuellig